Allergy

>

Latest News

Clinical Focus Business Focus Spotlight TGIF for Optinose Xhance: PDUFA Date Set for Saturday, March 16, 2024 / image credit nasal passages: ©turhanerbas/stock.adobe.com
Optinose Xhance approved by FDA as first medical therapy for CRS

March 15th 2024

Now FDA approved, Optinose’s Xhance is the first nonsurgical option for chronic rhinosinusitis both with and without nasal polyps.

Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose / image credit: ©New Africa/AdobeStock
Neffy May be Safe, Effective for Treatment of Urticaria Flares: Daily Dose

March 7th 2024

Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers / image credit: epipen injection: ©Rob Byron/stock.adobe.com
Needle-free Epinephrine Delivery: Perceptions of Physicians, Patients, and Caregivers

February 27th 2024

New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares / Image credit: ©chomplearn 2001/AdobeStock
New Data Suggest neffy May be Safe, Effective for Treatment of Urticaria Flares

February 26th 2024

Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA / image credit pollen, allergy: ©jovan vitanovski/shutterstock.com
Neffy Generates Favorable PK/PD Data Under Nasal Allergen Challenge in Repeat Dosing Study Requested by FDA

February 26th 2024

Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.